Aurora A is a prognostic marker for breast cancer arising in BRCA2 mutation carriers

被引:20
作者
Aradottir, Margret [1 ]
Reynisdottir, Sigridur T. [1 ]
Stefansson, Olafur A. [1 ]
Jonasson, Jon G. [2 ,3 ,4 ]
Sverrisdottir, Asgerdur [5 ]
Tryggvadottir, Laufey [2 ,3 ]
Eyfjord, Jorunn E. [1 ]
Bodvarsdottir, Sigridur K. [1 ]
机构
[1] Univ Iceland, Sch Hlth Sci, Canc Res Lab, Biomed Ctr,Fac Med, Vatnsmyrarvegi 16, IS-101 Reykjavik, Iceland
[2] Univ Iceland, Sch Hlth Sci, Fac Med, Reykjavik, Iceland
[3] Icelandic Canc Soc, Icelandic Canc Registry, Reykjavik, Iceland
[4] Natl Univ Hosp Reykjavik, Dept Pathol, Reykjavik, Iceland
[5] Natl Univ Hosp Reykjavik, Dept Med Oncol, Reykjavik, Iceland
关键词
breast cancer; Aurora A; BRCA2; prognosis; wild type allele loss; adjuvant treatment;
D O I
10.1002/cjp2.6
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Overexpression of the Aurora A kinase has been shown to have prognostic value in breast cancer. Previously, we showed a significant association between AURKA gene amplification and BRCA2 mutation in breast cancer. The aim of this study was to assess the prognostic impact of Aurora A overexpression on breast cancer arising in BRCA2 mutation carriers. Aurora A expression was evaluated by immunohistochemistry on breast tumour tissue microarrays from 107 BRCA2 999del5 mutation carriers and 284 of sporadic origin. Prognostic value of Aurora A nuclear staining was estimated in relation to clinical markers and adjuvant treatment, using multi-variate Cox's proportional hazards ratio regression model. BRCA2 wild-type allele loss was measured by Taq-Man in BRCA2 mutated tumour samples. All statistical tests were two sided. Multivariate analysis of breast cancer-specific survival, including proliferative markers and treatment, indicated independent prognostic value of Aurora A nuclear staining for BRCA2 mutation carriers (hazards ratio = 7.06; 95% confidence inter val = 1.23-40.6; p = 0.028). Poor breast cancer-specific survival of BRCA2 mutation carriers was found to be significantly associated with combined Aurora A nuclear expression and BRCA2 wild type allele loss in tumours (p < 0.001). Multivariate analysis indicated independent prognostic value of both positive Aurora A nuclear staining (hazards ratio = 10.09; 95% confidence interval = 1.19-85.4, p = 0.034) and BRCA2 wild type allele loss (hazards ratio = 9.63; 95% confidence interval = 1.81-51.0, p = 0.008) for BRCA2 mutation carriers. Aurora A nuclear expression was found to be a significant prognostic marker for BRCA2 mutation carriers, independent of clinical parameters and adjuvant treatment. Our conclusion is that treatment benefits for BRCA2 mutation carriers and sporadic breast cancer patients with Aurora A positive tumours may be enhanced by giving attention to Aurora A targeted treatment.
引用
收藏
页码:33 / 40
页数:8
相关论文
共 45 条
  • [1] Prognostic Discrimination Using a 70-Gene Signature among Patients with Estrogen Receptor-Positive Breast Cancer and an Intermediate 21-Gene Recurrence Score
    Ahn, Sung Gwe
    Lee, Hak Min
    Lee, Hak Woo
    Lee, Seung Ah
    Lee, Se-Ra
    Leem, Sun-Hee
    Jeong, Joon
    Chu, In-Sun
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2013, 14 (12) : 23685 - 23699
  • [2] Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer
    Ali, H. R.
    Dawson, S-J
    Blows, F. M.
    Provenzano, E.
    Pharoah, P. D.
    Caldas, C.
    [J]. BRITISH JOURNAL OF CANCER, 2012, 106 (11) : 1798 - 1806
  • [3] AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol
    Anand, S
    Penrhyn-Lowe, S
    Venkitaraman, AR
    [J]. CANCER CELL, 2003, 3 (01) : 51 - 62
  • [4] Aurora-A amplification associated with BRCA2 mutation in breast tumours
    Bodvarsdottir, Sigridur K.
    Hilmarsdottir, Holmfridur
    Birgisdottir, Valgerdur
    Steinarsdottir, Margret
    Jonasson, Jon G.
    Eyfjord, Jorunn E.
    [J]. CANCER LETTERS, 2007, 248 (01) : 96 - 102
  • [5] Dysfunctional telomeres in human BRCA2 mutated breast tumors and cell lines
    Bodvarsdottir, Sigridur K.
    Steinarsdottir, Margret
    Bjarnason, Hordur
    Eyfjord, Jorunn E.
    [J]. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2012, 729 (1-2) : 90 - 99
  • [6] Development of a Prognostic Model for Breast Cancer Survival in an Open Challenge Environment
    Cheng, Wei-Yi
    Yang, Tai-Hsien Ou
    Anastassiou, Dimitris
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2013, 5 (181)
  • [7] The mitotic kinase Aurora-A promotes distant metastases by inducing epithelial-to-mesenchymal transition in ERα+ breast cancer cells
    D'Assoro, A. B.
    Liu, T.
    Quatraro, C.
    Amato, A.
    Opyrchal, M.
    Leontovich, A.
    Ikeda, Y.
    Ohmine, S.
    Lingle, W.
    Suman, V.
    Ecsedy, J.
    Iankov, I.
    Di Leonardo, A.
    Ayers-Ringler, J.
    Degnim, A.
    Billadeau, D.
    McCubrey, J.
    Ingle, J.
    Salisbury, J. L.
    Galanis, E.
    [J]. ONCOGENE, 2014, 33 (05) : 599 - 610
  • [8] Abnormal cytokinesis in cells deficient in the breast cancer susceptibility protein BRCA2
    Daniels, MJ
    Wang, YM
    Lee, MY
    Venkitaraman, AR
    [J]. SCIENCE, 2004, 306 (5697) : 876 - 879
  • [9] Dedic PN, 2013, MED ONCOL, V30, P523
  • [10] Ferchichi I, 2013, DIS MARKERS, V34, P63, DOI [10.1155/2013/871929, 10.3233/DMA-120947]